Psoriasis Clinical Trials in Las Vegas

View 9 new treatments for Psoriasis in Las Vegas, NV, and other areas near me, such as Henderson. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.
View 12 trials in Las Vegas
Filter (12)

Deucravacitinib for Psoriasis

Bristol-Myers Squibb Clinic, Las Vegas + 2 more

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Waitlist
Phase 4
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director

Brodalumab for Pediatric Psoriasis

Bausch Clinic, Henderson + 1 more

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 12 Weeks
Varsha Bhatt
Study Director

Guselkumab for Psoriatic Arthritis

Janssen Clinic, Las Vegas + 1 more

This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

IDP-118 Lotion for Psoriasis

Bausch Clinic, Henderson + 1 more

This trial tests a special lotion called IDP-118 for children with moderate to severe plaque psoriasis. It aims to ensure the lotion is safe, see how much gets into the body, and check if it affects stress-related hormones. The goal is to find a safe and effective treatment for these children. IDP-118 is a combination of halobetasol propionate and tazarotene, which has shown effectiveness in treating moderate-to-severe plaque psoriasis in adults.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Anya Loncaric
Study Director

TAK-279 for Plaque Psoriasis

Takeda Clinic, Henderson + 1 more

This trial is testing a new drug called TAK-279 to see if it can help people with moderate to severe plaque psoriasis. The goal is to find out if TAK-279 can reduce the skin problems better than other available treatments.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Study Director
Study Director

Deucravacitinib for Psoriasis

Bristol-Myers Squibb Clinic, Las Vegas + 1 more

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Bristol-Myers Squibb
Study Director

Ixekizumab + Tirzepatide for Psoriasis

Eli Lilly Clinic, Las Vegas + 2 more

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Tapinarof Cream for Plaque Psoriasis

Teva Clinic, Las Vegas + 1 more

To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

TAK-279 for Psoriasis

Takeda Clinic, Henderson + 2 more

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Study Director
Study Director

Risankizumab for Pediatric Psoriasis

AbbVie Clinic, Reno + 1 more

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study evaluates adverse events and change in disease activity with risankizumab in pediatric participants with moderate to severe plaque psoriasis who completed the study M19-977. Risankizumab is an approved drug for treatment of moderate to severe plaque psoriasis in adults and is being studied in the pediatric population (6 to 17 years). A maximum of 132 participants will be enrolled in the study across approximately 50 sites worldwide. Participants will receive subcutaneous injection of risankizumab every 12 weeks for 204 weeks and are followed up for safety for 20 weeks after last dose. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
ABBVIE INC.
Study Director
Page 1 of 2

Frequently Asked Questions

How much do psoriasis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do psoriasis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across psoriasis trials in Las Vegas, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for psoriasis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.